Eisai cuts sales outlook on US weakness for Aciphex
This article was originally published in Scrip
Eisai has cut back its sales forecast for the fiscal year ending March 31st, pointing to the continued impact of the strong yen and generic threats to one of its mainstay products.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.